Circular RNA vaccines against SARS-CoV-2 and emerging variants

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants of concern (VOC), such as Delta (B.1.617.2) and Omicron (B.1.1.529), has continued to drive the worldwide pandemic. Therefore, there is a high demand for vaccines with enhanced efficacy, high thermostability, superior design flexibility, and fast manufacturing speed. Here, we report a circular RNA (circRNA) vaccine that encodes the trimeric RBD of SARS-CoV-2 Spike protein. Without the need of nucleotide modification, 5’-capping or 3’-polyadenylation, circRNA could be rapidly produced via in vitro transcription and is highly thermostable whether stored in naked or lipid-nanoparticle (LNP)-encapsulated format. LNP-encapsulated circRNA RBD elicited potent neutralizing antibodies and T cell responses, providing robust protection against Beta (B.1.351) and native viruses in mice and rhesus macaques, respectively. Notably, circRNA vaccine enabled higher and more durable antigen production than 1mΨ-modified mRNA vaccine, eliciting a higher proportion of neutralizing antibodies and stronger Th1-biased immune responses. Importantly, we found that circRNA RBD-Omicron vaccine induced effective neutralizing antibodies against only Omicron but not Delta variant. By contrast, circRNA RBD-Delta could elicit high level of neutralizing antibodies against both Delta and Omicron. Following two doses of either native- or Delta-specific vaccination, circRNA RBD-Delta , but not Omicron or Beta vaccines, could effectively boost the neutralizing antibodies against both Delta and Omicron variants. These results suggest that circRNA RBD-Delta is a favorable choice for vaccination to provide a broad-spectrum protection against the current variants of concern of SARS-CoV-2.

Cited by papers we hold 15

• A UFD1 variant encoding a microprotein modulates UFD1f and IPMK ubiquitination to play pivotal roles in anti-stress responses · 2025
  Not checked
• Circular RNAs as Targets for Developing Anticancer Therapeutics · 2025
  Not checked
• Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications · 2025
  Not checked
• mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications · 2023
  No notice
• Circular RNA vaccine induces potent T cell responses · 2023
  No notice
• CircRNAs in colorectal cancer: potential biomarkers and therapeutic targets · 2023
  No notice
• Research Advances on the Stability of mRNA Vaccines · 2023
  No notice
• Exosomal circRNA: emerging insights into cancer progression and clinical application potential · 2023
  No notice
• Circular RNA vaccine in disease prevention and treatment · 2023
  No notice
• Advances in Circular RNA and Its Applications · 2022
  No notice
• Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies · 2022
  No notice
• Advances in COVID-19 mRNA vaccine development · 2022
  No notice
• Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance · 2022
  No notice
• RNA-based therapeutics: an overview and prospectus · 2022
  No notice
• Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.